Brawn Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Brawn Biotech şirketinin toplam hissedar öz sermayesi ₹42.3M ve toplam borcu ₹0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹139.1M ve ₹96.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

₹0

Borç

Faiz karşılama oranı	n/a
Nakit	₹2.41m
Eşitlik	₹42.31m
Toplam yükümlülükler	₹96.81m
Toplam varlıklar	₹139.12m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 530207 'nin kısa vadeli varlıkları ( ₹130.6M ) kısa vadeli yükümlülüklerini ( ₹96.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 530207 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 530207 borçsuzdur.

Borcun Azaltılması: 530207 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 530207 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 530207 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Brawn Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings released: ₹0.96 loss per share (vs ₹1.43 loss in 2Q 2024)

Brawn Biotech Limited to Report Q2, 2025 Results on Nov 14, 2024

Brawn Biotech Limited, Annual General Meeting, Sep 30, 2024

Brawn Biotech Limited Announces Resignation of Independent Directors

Brawn Biotech Limited Announces Resignation of Independent Directors

First quarter 2025 earnings released: ₹1.83 loss per share (vs ₹0.58 loss in 1Q 2024)

Brawn Biotech Limited to Report Q1, 2025 Results on Aug 14, 2024

Insufficient new directors

Full year 2024 earnings released: ₹5.14 loss per share (vs ₹2.89 loss in FY 2023)

New minor risk - Financial data availability

Brawn Biotech Limited to Report Q4, 2024 Results on May 29, 2024

Brawn Biotech Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: ₹1.43 loss per share (vs ₹1.25 loss in 2Q 2023)

Brawn Biotech Limited to Report Q2, 2024 Results on Nov 10, 2023

Insufficient new directors

Brawn Biotech Limited, Annual General Meeting, Sep 25, 2023

New minor risk - Financial data availability

Brawn Biotech Limited to Report Q1, 2024 Results on Aug 09, 2023

Investor sentiment improves as stock rises 15%

Brawn Biotech Limited to Report Q4, 2023 Results on May 29, 2023

Third quarter 2023 earnings released: ₹0.18 loss per share (vs ₹5.29 loss in 3Q 2022)

Brawn Biotech Limited to Report Q3, 2023 Results on Feb 14, 2023

Insufficient new directors

Brawn Biotech Limited to Report Q2, 2023 Results on Nov 12, 2022

Insufficient new directors

Brawn Biotech Limited, Annual General Meeting, Sep 24, 2022

First quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.75 loss in 1Q 2022)

Brawn Biotech Limited Appoints Pooja Pandey as the Chief Financial Officer of the Company

Brawn Biotech Limited to Report Q1, 2023 Results on Aug 05, 2022

Brawn Biotech Limited Announces Resignation of Rati Garg as Chief Financial Officer

Full year 2022 earnings released: ₹5.25 loss per share (vs ₹1.84 loss in FY 2021)

Brawn Biotech Limited to Report Q4, 2022 Results on May 25, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: ₹1.37 loss per share (vs ₹0.27 profit in 2Q 2021)

First quarter 2022 earnings released: ₹0.75 loss per share (vs ₹0.93 loss in 1Q 2021)

Full year 2021 earnings released: ₹1.55 loss per share (vs ₹1.97 profit in FY 2020)

Third quarter 2021 earnings released: EPS ₹0.60 (vs ₹0.15 in 3Q 2020)

Brawn Biotech Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹25.00

Second quarter 2021 earnings released: EPS ₹0.27

New 90-day low: ₹19.10

Brawn Biotech Limited to Report Q2, 2021 Results on Nov 10, 2020

New 90-day low: ₹21.75

Earnings released

Brawn Biotech Limited to Report Q1, 2021 Results on Aug 21, 2020

New 90-day high - ₹29.90

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin